Preparing your experience
As temperature-sensitive medicines move through more complex international supply chains, coordinated handling, monitoring and contingency planning are essential to protect product quality.
A pharmaceutical shipment can leave a manufacturing facility perfectly prepared, travel thousands of kilometres and arrive at its destination on schedule.
Yet there is one question that matters more than the delivery deadline:
Did the medicine remain within the conditions required to protect its quality?
That question is becoming increasingly important as pharmaceutical supply chains move more temperature-sensitive products across international markets.
The logistics challenge is changing. Businesses are not simply transporting medicines from one warehouse to another. They are coordinating specialised packaging, temperature monitoring, multiple transportation partners, customs processes and increasingly complex distribution networks.
And the financial stakes are growing.
According to IQVIA, the pharmaceutical cold chain accounted for approximately 38% of the pharmaceutical market in 2024, compared with 26% in 2017. Cold chain logistics expenditure was estimated at around $21.3 billion in 2024.
Source: IQVIA, The Economic and Environmental Impact of the Vaccine Cold Chain
These figures highlight a significant shift in pharmaceutical distribution.
As temperature-sensitive products become a more prominent part of the industry, transportation conditions are increasingly central to supply chain performance.
The question is no longer simply how quickly pharmaceutical freight can move.
It is how reliably businesses can protect the product throughout its journey.
Pharmaceutical logistics is entering a period of increasing operational complexity.
Biologics, vaccines, specialty medicines and other temperature-sensitive products require transportation arrangements that differ significantly from conventional freight.
The implications extend beyond the pharmaceutical manufacturer.
Freight forwarders, carriers, warehouses and distribution partners must coordinate around product-specific requirements.
This is particularly relevant in India.
According to Mordor Intelligence, the Indian healthcare cold chain logistics market is estimated at $9.27 billion in 2026, with projections reaching $12.40 billion by 2031.
That represents an estimated compound annual growth rate of approximately 5.99% over the forecast period.
The report also identifies transportation as the largest logistics function, accounting for 52.47% of the market in 2025.
Source: Mordor Intelligence, India Healthcare Cold Chain Logistics Market
These estimates illustrate the scale of the opportunity.
But growth alone does not guarantee reliability.
As pharmaceutical distribution expands, businesses must ensure that transportation infrastructure, monitoring systems and handling procedures can support increasingly demanding product requirements.
The commercial opportunity is expanding. The operational responsibility is expanding with it.
For logistics providers, this creates a clear strategic priority: pharmaceutical freight must be planned around product integrity rather than treated as conventional cargo with additional labels.
Consider a shipment of temperature-sensitive medicines travelling through an international airport.
The aircraft arrives.
The cargo is unloaded.
But the shipment remains on the airport apron longer than expected.
The delay may appear insignificant compared with the overall journey.
However, exposure to unsuitable temperatures can create a quality concern even when the shipment arrives physically intact.
The World Health Organization has documented temperature-related vulnerabilities in vaccine supply chains.
Its temperature-monitoring evidence brief explains that studies in industrialised and developing countries have identified vaccine exposure to damaging temperatures, particularly freezing conditions.
Source: WHO, Temperature Monitoring Study
This is an important distinction.
Cold chain management is not simply about keeping products cold.
It is about maintaining the specific temperature conditions required by the product.
Some medicines require refrigeration. Others require controlled room-temperature conditions. Certain products are particularly sensitive to freezing.
The correct transportation conditions must therefore be established using the product's approved storage requirements and relevant stability information.
For pharmaceutical freight, the risk may emerge during:
The challenge is that these risks can occur between transportation stages, precisely where responsibility and visibility may become fragmented.
That makes temperature monitoring, coordinated handling and contingency planning essential.
Good Distribution Practice (GDP) provides a framework for protecting medicines throughout distribution.
But pharmaceutical businesses must recognise an important operational reality.
A compliant warehouse does not automatically produce a compliant transportation process.
The shipment may be stored correctly before dispatch, but its condition must also be protected during transportation.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) identifies transportation as a significant area for quality risk management.
Its guidance explains that businesses should identify transportation risks, assess their potential impact and implement appropriate controls.
The regulator also highlights the importance of monitoring, suitable equipment and scientifically justified decisions when temperature excursions occur.
Source: MHRA Inspectorate, Applying Quality Risk Management to GDP Transportation Risks
This has practical implications for logistics planning.
Product requirements: What temperature conditions must be maintained?
Transportation suitability: Is the selected vehicle, packaging or shipping solution appropriate?
Monitoring: How will transportation conditions be recorded and assessed?
Responsibility: Who manages the shipment at each stage?
Contingency planning: What happens if transportation is delayed or equipment fails?
The European Commission's GDP guidelines also emphasise protecting medicinal products against damage, adulteration and theft while maintaining appropriate transportation conditions.
Source: European Commission, Good Distribution Practice Guidelines
The strategic lesson is clear.
GDP should influence transportation decisions before a shipment is booked, not simply become a document reviewed after delivery.
Air freight is frequently selected for pharmaceutical shipments because transportation speed can be commercially important.
But the aircraft is only one part of the transportation process.
A shipment may spend time in collection vehicles, airport warehouses, security screening, loading areas and destination handling facilities.
Each transfer creates another opportunity for delays or exposure.
The UK government's pharmaceutical air freight guidance specifically identifies airport tarmac exposure as a significant temperature-related vulnerability.
It recommends minimising exposure during loading and unloading, coordinating with service providers and establishing transportation controls.
Source: UK Government, Guidance on Air Freight of Medicines
This creates an important distinction between flight duration and total transportation performance.
A short flight does not necessarily mean a low-risk shipment.
The overall journey must account for collection, airport handling, customs clearance, transfers and final delivery.
For pharmaceutical logistics, the most effective transportation plan is one that minimises unnecessary handoffs and establishes clear responsibilities across the entire route.
Imagine a shipment reaches its destination after an unexpected delay.
The consignee asks whether the product remained within its required conditions.
The logistics team must establish what happened.
Without appropriate monitoring records, handling information and transportation documentation, the investigation becomes more difficult.
This is where traceability becomes commercially important.
What product was shipped?
Which transportation conditions applied?
Which organisations handled the shipment?
Were delays or deviations recorded?
What evidence supports the transportation process?
The WHO's 2025 guidance on international vaccine packaging and shipping addresses the complex journey from manufacturer to recipient country.
It specifically considers transportation, quality checks, temperature requirements and the responsibilities of logistics service providers, freight forwarders and carriers.
Source: WHO, Guidelines for the International Packaging and Shipping of Vaccines, 7th Edition, published July 2025
This reinforces the importance of integrating documentation and monitoring into transportation planning.
For businesses managing international pharmaceutical freight, shipment visibility should support decision-making rather than simply provide a tracking update.
A pharmaceutical transportation deviation can create several operational consequences.
The shipment may require investigation.
Delivery schedules may be disrupted.
Additional transportation or handling arrangements may become necessary.
Product suitability may need to be assessed.
The commercial impact depends on the product, the nature of the deviation and the transportation circumstances.
However, the underlying principle is straightforward.
Preventing a transportation problem is generally more effective than discovering it after delivery.
This is why pharmaceutical freight planning should incorporate risk assessment before dispatch.
Businesses should consider the route, transportation duration, packaging suitability, environmental conditions and potential disruptions.
Monitoring should also be appropriate to the product and the transportation process.
The objective is to identify potential problems early enough for the responsible teams to take suitable action.
For logistics providers, this creates an opportunity to deliver more than transportation capacity.
It creates an opportunity to support better shipment coordination, visibility and operational risk management.
As pharmaceutical cold chain distribution expands, logistics teams should focus on five operational priorities.
Establish the product's transportation requirements before selecting the freight solution.
Choose appropriate packaging, vehicles and handling procedures based on the shipment's requirements.
Establish clear responsibilities across manufacturers, freight forwarders, carriers and receiving organisations.
Maintain appropriate shipment records and temperature-monitoring information where required.
Prepare for delays, equipment failures, transportation disruptions and temperature excursions.
These measures help integrate compliance into daily freight operations.
They also support a more informed approach to transportation decisions, particularly when shipments involve multiple countries, transportation modes or handling partners.
Conclusion: Pharmaceutical Freight Is a Quality Responsibility
The pharmaceutical cold chain is expanding.
Market estimates point to growing investment in temperature-sensitive transportation, while WHO and regulatory guidance continue to highlight the importance of protecting medicines throughout distribution.
For logistics businesses, this creates a challenge that extends beyond delivery speed.
The real objective is to coordinate transportation in a way that supports product quality, regulatory requirements and supply chain reliability.
Because a pharmaceutical shipment is not successful simply when it reaches its destination.
It is successful when it arrives under the conditions required to protect the product.
At Clarusto Logistics, we understand the importance of coordinated freight planning, international transportation and customs processes in complex supply chains.
For businesses managing pharmaceutical freight and international cargo, the starting point is understanding the shipment's requirements and planning the journey accordingly.
Explore our freight forwarding services and customs clearance solutions to learn more about coordinating international freight operations.
In pharmaceutical logistics, the journey is not just about moving cargo. It is about protecting what the cargo represents.
Pharmaceutical freight compliance involves following applicable regulatory requirements, transportation procedures and product handling conditions to protect medicines throughout distribution.
The increasing importance of temperature-sensitive medicines, vaccines and biologics is driving demand for specialised transportation, monitoring and cold chain infrastructure.
Potential risks include temperature excursions, unsuitable packaging, transportation delays, inadequate monitoring, security concerns and poor coordination between logistics partners.
No. Transportation requirements depend on the product's approved storage conditions. Some medicines require refrigeration, while others require different temperature conditions.
Businesses should establish product requirements before dispatch, select appropriate transportation partners, maintain monitoring and documentation, and prepare contingency procedures.
Part of Clarusto Group · A Clarusto Group Company
© 2025 Clarusto Logistics. All rights reserved. | Privacy Policy | Terms of Service